Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann Lindsay

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
The American Journal of Tropical Medicine and Hygiene|August 3, 2012
Outbreak of human trichinellosis in Northern California caused by Trichinella murrelliRebecca L Hall, Ann Lindsay, Chris Hammond, et al.
Journal of the National Cancer Institute|May 20, 2004
Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancerMark D Pegram, Tadeusz Pienkowski, Donald W Northfelt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2011
Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trialWolfgang Eiermann, Tadeusz Pienkowski, John Crown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2010
Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapyMichael F Press, Guido Sauter, Marc Buyse, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2016
HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical TrialsMichael F Press, Guido Sauter, Marc Buyse, et al.
The Lancet. Oncology|June 21, 2015
Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trialSara A Hurvitz, Fabrice Andre, Zefei Jiang, et al.
The New England Journal of Medicine|October 14, 2011
Adjuvant trastuzumab in HER2-positive breast cancerDennis Slamon, Wolfgang Eiermann, Nicholas Robert, et al.
The Lancet. Oncology|March 25, 2011
Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled studyMiguel Martin, Henri Roche, Tamas Pinter, et al.
The Lancet. Oncology|December 19, 2012
Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trialJohn R Mackey, Miguel Martin, Tadeusz Pienkowski, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
The American Journal of Tropical Medicine and Hygiene|August 3, 2012
Outbreak of human trichinellosis in Northern California caused by Trichinella murrelliRebecca L Hall, Ann Lindsay, Chris Hammond, et al.
Journal of the National Cancer Institute|May 20, 2004
Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancerMark D Pegram, Tadeusz Pienkowski, Donald W Northfelt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2011
Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trialWolfgang Eiermann, Tadeusz Pienkowski, John Crown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2010
Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapyMichael F Press, Guido Sauter, Marc Buyse, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2016
HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical TrialsMichael F Press, Guido Sauter, Marc Buyse, et al.
The Lancet. Oncology|June 21, 2015
Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trialSara A Hurvitz, Fabrice Andre, Zefei Jiang, et al.
The New England Journal of Medicine|October 14, 2011
Adjuvant trastuzumab in HER2-positive breast cancerDennis Slamon, Wolfgang Eiermann, Nicholas Robert, et al.
The Lancet. Oncology|March 25, 2011
Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled studyMiguel Martin, Henri Roche, Tamas Pinter, et al.
The Lancet. Oncology|December 19, 2012
Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trialJohn R Mackey, Miguel Martin, Tadeusz Pienkowski, et al.
Pageof 2